H1N1 疫苗市場 - 全球產業規模、佔有率、趨勢、機會和預測，按給藥途徑、品牌類型、配銷通路、地區和競爭細分，2020-2030 年預測

2024 年全球 H1N1 疫苗市值為 99.1 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 4.23%。全球 H1N1 疫苗市場是醫療保健產業的重要組成部分，主要著重於預防和控制 H1N1 流感病毒（俗稱豬流感）的傳播。全球 H1N1 疫苗市場受到多種因素推動，主要是流感疫情的盛行率上升和人們對疫苗接種計劃的認知不斷提高。世界各國政府和醫療保健組織正在投資免疫計劃，以預防季節性流感和大流行性流感，推動了對 H1N1 疫苗的需求。老年人口的不斷成長，使得 H1N1 感染者更容易出現嚴重的併發症，這進一步促進了市場的成長。例如，根據美國疾病管制與預防中心在 2023 年 10 月發布的估計，全球季節性流感病例將接近 10 億例，其中約 300 萬至 500 萬例為重症。國家和全球層面加強監測力度和政府對疫苗接種的強力支持（重點監測分發、供應和管理）是推動市場成長的關鍵因素。

疫苗開發的進步，包括重組疫苗和佐劑疫苗，提高了疫苗功效並推動了疫苗的採用。新的H1N1病毒株的出現需要疫苗的不斷更新，從而支持市場擴張。不斷增加的研發活動、世界衛生組織和疾病預防控制中心等全球衛生組織的資助以及製藥公司之間的策略合作促進了疫苗的快速開發和分發。 COVID-19 疫情提高了民眾對呼吸道感染的認知，並加強了整體疫苗基礎設施。政府擴大對高風險族群流感疫苗接種的要求，加上優惠的報銷政策，進一步刺激了市場成長。疫苗生產的技術進步，包括基於細胞和 mRNA 平台，提高了效率和可擴展性。因此，對提供更廣泛流感保護的聯合疫苗的需求不斷成長，預計將在未來幾年推動創新和市場擴張。

主要市場促進因素

疫情防範與意識

主要市場挑戰

病毒突變和進化

主要市場趨勢

通用流感疫苗

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球 H1N1 疫苗市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依給藥途徑分類（皮內疫苗、肌肉注射疫苗、鼻內疫苗）
  • 依品牌類型（Agripal、Fiuarix、Influgen、Influvac、Nasovac、Vaxigrip）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 產品市場圖
  • 依給藥途徑
  • 按品牌類型
  • 按配銷通路
  • 按地區

第 6 章：北美 H1N1 疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲 H1N1 疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 法國
  • 義大利
  • 西班牙

第 8 章：亞太地區 H1N1 疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 日本
  • 印度
  • 澳洲
  • 韓國

第 9 章：南美洲 H1N1 疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲 H1N1 疫苗市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 科威特

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 近期發展
• 合併與收購
• 產品發布

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• AstraZeneca PLC

。 14.1.1.業務概覽

• 產品供應
• 最新動態
• 財務狀況（據報告）
• 主要人員
• SWOT 分析
• 賽諾菲巴斯德默沙東
• 葛蘭素史克公司
• 雅培實驗室公司
• 加拿大行動通訊有限公司
• 輝瑞公司
• CPL Biologicals Pvt Ltd
• 田邊三菱製藥公司
• 科興生物科技股份有限公司
• Zydus 生命科學有限公司

第 15 章：策略建議

第16章調查會社について,免責事項

Global H1N1 Vaccines Market was valued at USD 9.91 billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 4.23% through 2030. The global H1N1 vaccines market is a crucial component of the healthcare industry, primarily focused on preventing and controlling the spread of the H1N1 influenza virus, commonly known as swine flu. The global H1N1 vaccines market is driven by multiple factors, primarily the rising prevalence of influenza outbreaks and the increasing awareness of vaccination programs. Governments and healthcare organizations worldwide are investing in immunization initiatives to prevent seasonal and pandemic influenza, fueling demand for H1N1 vaccines. The growing elderly population, which is more susceptible to severe complications from H1N1 infections, further boosts market growth. For instance, according to CDC estimates published in October 2023, nearly one billion cases of seasonal influenza occur worldwide, with approximately 3-5 million classified as severe. The increased surveillance efforts and strong government support for vaccination at both national and global levels-focusing on monitoring distribution, supply, and administration-are key factors driving market growth.

Advancements in vaccine development, including recombinant and adjuvanted vaccines, enhance efficacy and drive adoption. The emergence of new H1N1 virus strains necessitates continuous vaccine updates, supporting market expansion. Increasing R&D activities, funding from global health organizations such as the WHO and CDC, and strategic collaborations among pharmaceutical companies contribute to the rapid development and distribution of vaccines. The COVID-19 pandemic has heightened public awareness of respiratory infections, strengthening the overall vaccine infrastructure. Expanding government mandates for influenza vaccination in high-risk groups, coupled with favorable reimbursement policies, further stimulate market growth. Technological advancements in vaccine production, including cell-based and mRNA platforms, offer improved efficiency and scalability. Therefore, the rising demand for combination vaccines that provide broader influenza protection is expected to drive innovation and market expansion in the coming years.

Key Market Drivers

Pandemic Preparedness and Awareness

Pandemic preparedness and awareness play a crucial role in driving the growth of the global H1N1 vaccines market. Governments, health organizations, and pharmaceutical companies have intensified efforts to strengthen pandemic response strategies, ensuring rapid vaccine development, stockpiling, and distribution. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) continue to promote global surveillance programs, early detection systems, and public awareness campaigns, increasing the demand for H1N1 vaccines. The COVID-19 pandemic has further underscored the importance of robust vaccination programs, leading to improved healthcare infrastructure and vaccine supply chains. Growing public awareness about the risks of influenza pandemics has encouraged higher vaccination rates, particularly among vulnerable populations such as the elderly, pregnant women, and immunocompromised individuals. Governments worldwide are implementing mandatory vaccination policies for healthcare workers and high-risk groups, boosting market expansion. The pandemic preparedness initiatives have led to significant investments in vaccine research, resulting in the development of more effective and rapidly deployable H1N1 vaccines, including cell-based and mRNA-based formulations. Increased collaboration between public and private sectors has accelerated vaccine accessibility, further driving market growth. As global preparedness measures continue to evolve, the demand for H1N1 vaccines is expected to rise, ensuring better pandemic resilience. According to the World Health Organization (WHO), seasonal influenza causes approximately 3 to 5 million cases of severe illness and between 290,000 to 650,000 respiratory-related deaths annually. In industrialized countries, the majority of influenza-related deaths occur in individuals over 65 years old. Seasonal influenza can lead to a wide range of health outcomes, from mild illness to severe complications and even death.

Key Market Challenges

Virus Mutations and Evolution

Perhaps the most significant challenge in the H1N1 vaccines market is the constant evolution of the virus. H1N1 influenza strains mutate regularly, making it necessary to update vaccine formulations to match the currently circulating strains. This requires ongoing research, surveillance, and timely adjustments in vaccine production, driving the need for advanced manufacturing technologies and robust global monitoring systems. Governments and health organizations, such as the WHO and CDC, play a crucial role in identifying dominant strains and recommending vaccine updates, ensuring continued market demand. The pharmaceutical companies invest heavily in innovative vaccine platforms, such as mRNA and cell-based technologies, to enable faster production and adaptability to viral mutations. The unpredictable nature of influenza outbreaks necessitates strategic vaccine stockpiling and rapid distribution systems, further fueling market growth. As global health preparedness efforts intensify, the demand for adaptable and effective H1N1 vaccines continues to rise, supporting the expansion of the market.

Key Market Trends

Universal Influenza Vaccines

One of the most promising trends driving the growth of the global H1N1 vaccines market is the development of universal influenza vaccines. Unlike traditional seasonal flu vaccines, which require frequent updates to match circulating strains, universal vaccines aim to provide long-lasting immunity against multiple influenza subtypes, including H1N1. These vaccines target conserved regions of the virus, such as hemagglutinin stalk domains and internal viral proteins, which undergo fewer mutations compared to surface antigens. By inducing broader immune responses, universal vaccines could significantly reduce the burden of annual vaccinations and enhance pandemic preparedness. Pharmaceutical companies and research institutions are actively investing in advanced vaccine platforms, including mRNA, viral vector, and nanoparticle-based approaches, to accelerate universal vaccine development. The growing support from governments and global health organizations is further driving clinical trials and regulatory approvals. A successful universal influenza vaccine could streamline vaccine manufacturing, reducing production costs and distribution challenges. This breakthrough would be particularly beneficial for low- and middle-income countries with limited healthcare resources, improving global access to influenza prevention. As research progresses and technological advancements continue, universal influenza vaccines have the potential to transform the H1N1 vaccines market, offering a more efficient and sustainable approach to combating influenza outbreaks worldwide.

Key Market Players

• AstraZeneca PLC
• Sanofi Pasteur MSD AG
• GSK PLC
• Abbott Laboratories Inc
• CSL Ltd
• Pfizer Inc
• CPL Biologicals Pvt Ltd
• Mitsubishi Tanabe Pharma Corp
• Sinovac Biotech Co Ltd
• Zydus Lifesciences Ltd

Report Scope:

In this report, the Global H1N1 Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

H1N1 Vaccines Market, By Route of Administration:

• Intradermal Vaccines
• Intramuscular Vaccines
• Intranasal Vaccines

H1N1 Vaccines Market, By Type of Brand:

• Agripal
• Fiuarix
• Influgen
• Influvac
• Nasovac
• Vaxigrip

H1N1 Vaccines Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

H1N1 Vaccines Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global H1N1 Vaccines Market.

Available Customizations:

Global H1N1 Vaccines market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global H1N1 Vaccines Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 5.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Route of Administration
  • 5.3.2. By Type of Brand
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America H1N1 Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 6.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States H1N1 Vaccines Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Type of Brand
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada H1N1 Vaccines Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Type of Brand
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico H1N1 Vaccines Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Type of Brand
      • 6.3.3.2.3. By Distribution Channel

7. Europe H1N1 Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 7.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany H1N1 Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Type of Brand
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom H1N1 Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Type of Brand
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France H1N1 Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Type of Brand
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy H1N1 Vaccines Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Type of Brand
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain H1N1 Vaccines Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Type of Brand
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific H1N1 Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 8.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China H1N1 Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Type of Brand
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan H1N1 Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Type of Brand
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India H1N1 Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Type of Brand
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia H1N1 Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Type of Brand
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea H1N1 Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Type of Brand
      • 8.3.5.2.3. By Distribution Channel

9. South America H1N1 Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 9.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil H1N1 Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Type of Brand
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina H1N1 Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Type of Brand
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia H1N1 Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Type of Brand
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa H1N1 Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration (Intradermal Vaccines, Intramuscular Vaccines, Intranasal Vaccines)
  • 10.2.2. By Type of Brand (Agripal, Fiuarix, Influgen, Influvac, Nasovac, Vaxigrip)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa H1N1 Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Type of Brand
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia H1N1 Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Type of Brand
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE H1N1 Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Type of Brand
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait H1N1 Vaccines Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Route of Administration
      • 10.3.4.2.2. By Type of Brand
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. AstraZeneca PLC

. 14.1.1. Business Overview

• 14.1.2. Product Offerings
• 14.1.3. Recent Developments
• 14.1.4. Financials (As Reported)
• 14.1.5. Key Personnel
• 14.1.6. SWOT Analysis
• 14.2. Sanofi Pasteur MSD AG
• 14.3. GSK PLC
• 14.4. Abbott Laboratories Inc
• 14.5. CSL Ltd
• 14.6. Pfizer Inc
• 14.7. CPL Biologicals Pvt Ltd
• 14.8. Mitsubishi Tanabe Pharma Corp
• 14.9. Sinovac Biotech Co Ltd
• 14.10. Zydus Lifesciences Ltd

15. Strategic Recommendations

16. About Us & Disclaimer